Regulatory Environment and Impact Analysis- Sterile Packaging Market Standards & Regulations, Regional & National Regulatory Bodies - Market Analysis & Forecast to 2020
“Growing demand from the healthcare industry to drive the market for sterile medical packaging”
The global market for sterile medical packaging is projected to grow from USD 26.55 billion in 2015 to reach USD 35.07 billion by 2020, at an estimated CAGR of 5.72%. The market for sterile medical packaging is driven by the growing demand from the healthcare industry due to increase in health awareness.
“Need for harmonization between the global standards and regulations in the sterile medical packaging market”
In line with the global applicable standards, each country may have its own specific set of applications and environments in which the product needs to perform. Having multiple standards may create confusion and trade barriers for manufacturers. Hence, in order to avoid this as well as to easily understand and implement packaging requirements, harmonization between the standards is necessary.
“Asia-Pacific projected to grow during the forecast period”
Asia-Pacific is projected to be the fastest-growing region in the sterile medical packaging market in the next five years. However, factors such as longer timelines for approving the medical devices in Australia, red tapism in India, and higher cost for the approval of medical devices make the regulatory framework in the region more complex.
Breakdown of Primaries:
Primary interviews were conducted with a number of industry experts in order to collect data related to different aspects of sterile medical packaging. Estimates reached after analyzing secondary sources were validated through these interviews. Primary sources include professionals such as sterile packaging manufacturers, distributors, and academic professionals. Distribution of primary interviews is as follows:
By Company Type: Tier 1 – 38%, Tier 2 – 38%, and Tier 3 – 24%
By Designation: C-level – 38%, Manager Level – 34%, and Others – 28%
By Region: North America – 32%, Europe – 28%, Asia-Pacific – 25%, and RoW – 15%
The tier of the companies is defined on the basis of their total revenue, as of 2014: Tier 1: Revenue USD 500 million, Tier 2: Revenue USD 100 to USD 500 million, and Tier 3: Revenue USD 100 million
Others include sales managers, marketing managers, and product managers.
Reasons to buy the report
The report will help the market leaders/new entrants in this market in the following ways:
1. This report segments the market for sterile medical packaging comprehensively and provides the closest approximations of the revenue numbers for the overall market across different regions.
2. The report helps stakeholders to understand the market and related regulations further providing them information on key market drivers, restraints, challenges, and opportunities.
3. The report helps to understand the regulatory aspects of the sterile medical packaging industry for the top key countries and regions.
The global market for sterile medical packaging is projected to grow from USD 26.55 billion in 2015 to reach USD 35.07 billion by 2020, at an estimated CAGR of 5.72%. The market for sterile medical packaging is driven by the growing demand from the healthcare industry due to increase in health awareness.
“Need for harmonization between the global standards and regulations in the sterile medical packaging market”
In line with the global applicable standards, each country may have its own specific set of applications and environments in which the product needs to perform. Having multiple standards may create confusion and trade barriers for manufacturers. Hence, in order to avoid this as well as to easily understand and implement packaging requirements, harmonization between the standards is necessary.
“Asia-Pacific projected to grow during the forecast period”
Asia-Pacific is projected to be the fastest-growing region in the sterile medical packaging market in the next five years. However, factors such as longer timelines for approving the medical devices in Australia, red tapism in India, and higher cost for the approval of medical devices make the regulatory framework in the region more complex.
Breakdown of Primaries:
Primary interviews were conducted with a number of industry experts in order to collect data related to different aspects of sterile medical packaging. Estimates reached after analyzing secondary sources were validated through these interviews. Primary sources include professionals such as sterile packaging manufacturers, distributors, and academic professionals. Distribution of primary interviews is as follows:
By Company Type: Tier 1 – 38%, Tier 2 – 38%, and Tier 3 – 24%
By Designation: C-level – 38%, Manager Level – 34%, and Others – 28%
By Region: North America – 32%, Europe – 28%, Asia-Pacific – 25%, and RoW – 15%
The tier of the companies is defined on the basis of their total revenue, as of 2014: Tier 1: Revenue USD 500 million, Tier 2: Revenue USD 100 to USD 500 million, and Tier 3: Revenue USD 100 million
Others include sales managers, marketing managers, and product managers.
Reasons to buy the report
The report will help the market leaders/new entrants in this market in the following ways:
1. This report segments the market for sterile medical packaging comprehensively and provides the closest approximations of the revenue numbers for the overall market across different regions.
2. The report helps stakeholders to understand the market and related regulations further providing them information on key market drivers, restraints, challenges, and opportunities.
3. The report helps to understand the regulatory aspects of the sterile medical packaging industry for the top key countries and regions.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 PERIODIZATION CONSIDERED FOR THE STERILE MEDICAL PACKAGING MARKET
1.4 CURRENCY CONSIDERED FOR THE STERILE MEDICAL PACKAGING MARKET
1.5 UNIT CONSIDERED FOR THE STERILE MEDICAL PACKAGING MARKET
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key Data From Secondary Sources
2.1.2 PRIMARY DATA
2.1.2.1 Key Data From Primary Sources
2.1.2.1.1 Breakdown of primaries by company type, designation & region
2.2 FACTOR ANALYSIS
2.2.1 INTRODUCTION
2.2.2 OVERVIEW OF PARENT INDUSTRY
2.2.3 DEMAND-SIDE ANALYSIS
2.2.3.1 Rising Population
2.2.3.1.1 Increase in the middle-class population, 2009–2030
2.2.3.2 Increasing Urban population
2.2.3.3 Developing Economies: GDP (Purchasing Power Parity)
2.2.4 SUPPLY-SIDE ANALYSIS
2.2.4.1 Fluctuation in Raw Material Prices
2.2.4.2 Increasing Investment in Research & Development to Develop Innovative Technologies
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS & LIMITATIONS
2.5.1 ASSUMPTIONS
2.5.2 LIMITATIONS
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 REGULATORY SCENARIO
3.2.1 REGULATORY FRAMEWORK IN NORTH AMERICA
3.2.2 REGULATORY FRAMEWORK IN ASIA-PACIFIC
3.2.3 REGULATORY FRAMEWORK IN EUROPE
3.2.4 REGULATORY FRAMEWORK IN ROW
3.3 MEDICAL DEVICE APPROVAL PROCESS IN KEY COUNTRIES
3.4 IMPACT ANALYSIS
3.4.1 CASE STUDY: MEDICAL DEVICE RECALL & ITS IMPACT
3.4.2 NEED FOR HARMONIZATION OF GLOBAL STANDARDS & REGULATIONS
4 MARKET OVERVIEW OF STERILE MEDICAL PACKAGING
4.1 INTRODUCTION
4.2 EVOLUTION
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.1.1 Increased Health Awareness
4.3.1.2 Growing Demand from Healthcare Industry
4.3.1.3 Aging Population
4.3.2 RESTRAINTS
4.3.2.1 Stringent Regulations
4.3.3 OPPORTUNITIES
4.3.3.1 New Product Development and Continuous Innovations in Pharmaceuticals
4.3.3.2 Developing New Sustainable Packaging Options
4.3.4 CHALLENGES
4.3.4.1 Maintaining Medical Packaging Integrity
4.3.4.2 Rise in Healthcare Cost
4.4 STERILE MEDICAL PACKAGE DEVELOPMENT
4.5 FUNCTIONS OF A STERILE MEDICAL PACKAGE
4.5.1 PROTECTION
4.5.2 EASE OF USE
4.5.3 IDENTIFICATION
4.5.4 PROCESSABILITY
4.5.5 SPECIAL APPLICATIONS
5 INTERNATIONAL GOVERNING BODIES
5.1 INTRODUCTION
5.2 AMERICAN SOCIETY FOR TESTING AND MATERIALS (ASTM)
5.2.1 ASTM COMMITTEE D10
5.2.1.1 D10.13
5.2.1.2 D10.19
5.2.1.3 D10.27
5.2.1.4 D10.32
5.2.2 ASTM COMMITTEE F02
5.2.2.1 F02.10
5.2.2.2 F02.15
5.2.2.3 F02.20
5.2.2.4 F02.40
5.2.2.5 F02.50
5.3 INTERNATIONAL ORGANIZATION OF STANDARDIZATION (ISO)
5.3.1 DEVELOPING ISO STANDARDS
5.3.1.1 Preliminary Stage
5.3.1.2 Proposal Stage
5.3.1.3 Preparatory Stage
5.3.1.4 Committee Stage
5.3.1.5 Enquiry Stage
5.3.1.6 Approval Stage
5.3.1.7 Publication Stage
5.3.2 STANDARDS RELATED TO STERILE MEDICAL PACKAGING
5.3.2.1 ISO 16775
5.3.2.2 ISO 11607
5.3.2.2.1 Application
5.3.2.2.2 Limitation
5.3.2.3 ISO 11607-1
5.3.2.4 ISO 11607-2
5.4 U.S. FOOD AND DRUG ADMINISTRATION (FDA)
5.5 INTERNATIONAL MEDICAL DEVICE REGULATORY FORUM (IMDRF)
6 REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN NORTH AMERICA
6.1 NORTH AMERICA
6.2 NORTH AMERICA: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
6.2.1 U.S.
6.2.2 KEY GOVERNING BODIES IN THE U.S.
6.2.2.1 FDA
6.2.2.1.1 Overview
6.2.2.1.2 Responsibilities
6.2.3 CANADA
6.2.4 KEY GOVERNING BODIES IN CANADA
6.2.4.1 Health Canada (HC)
6.2.4.1.1 Overview
6.2.4.1.2 Responsibilities
6.2.5 MEXICO
6.2.6 KEY GOVERNING BODIES IN MEXICO
6.2.6.1 Federal Commission for the Protection Against Sanitary Risk (COFEPRIS)
6.2.6.1.1 Overview
6.2.6.1.2 Responsibilities
7 REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN EUROPE
7.1 EUROPE
7.2 EUROPE: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
7.3 GOVERNING BODIES IN EUROPE
7.3.1 EUROPEAN COMMITTEE FOR STANDARDIZATION (CEN)
7.3.1.1 Overview
7.3.1.2 Standards Developed by CEN
7.3.1.2.1 Harmonization of EN 868-1 and ISO 11607
7.3.1.2.2 EN 868-2: 2009
7.3.1.2.3 EN 868-3:2009
7.3.1.2.4 EN 868-4:2009
7.3.1.2.5 EN 868-5:2009
7.3.1.2.6 EN 868-6:2009
7.3.1.2.7 EN 868-7:2009
7.3.1.2.8 EN 868-8:2009
7.3.1.2.9 EN 868-9:2009
7.3.1.2.10 EN 868-10:2009
7.3.2 STERILE BARRIER ASSOCIATION (SBA)
7.3.2.1 Overview
7.3.2.2 SBA Member Categories
7.3.2.3 Administering Activities
7.4 MEDICAL DEVICE REGULATIONS IN EUROPE
7.4.1 INTRODUCTION
7.4.2 MEDICAL DEVICE DIRECTIVE (93/42/EEC)
7.5 IMPACT OF MEDICAL DEVICE REGULATIONS IN EUROPE
7.5.1 CE MARKING- A GATEWAY TO ACCESS EUROPEAN MARKET
7.5.2 IMPACT OF HARMONIZATION BETWEEN EN AND ISO
7.6 KEY COUNTRIES IN EUROPE
7.6.1 GERMANY
7.6.2 KEY GOVERNING BODIES IN GERMANY
7.6.2.1 Federal Ministry of Health
7.6.2.1.1 Overview
7.6.2.1.2 Administering activities
7.6.2.2 German Institute for Standardization (DIN)
7.6.2.2.1 Overview
7.6.2.2.2 Organizational structure
7.6.2.2.3 Administering activities
7.6.3 U.K.
7.6.4 KEY GOVERNING BODIES IN THE U.K.
7.6.4.1 Medicines and Healthcare products Regulatory Agency (MHRA)
7.6.4.1.1 Overview
7.6.4.1.2 Responsibilities
7.6.4.2 Department of Health (DH)
7.6.4.2.1 Overview
7.6.4.2.2 Responsibilities
7.6.4.3 Association of British Healthcare Industries (ABHI)
7.6.4.3.1 Overview
7.6.4.3.2 Responsibilities
7.6.4.4 The British Standards Institution (BSI)
7.6.4.4.1 Overview
7.6.4.4.2 Responsibilities
7.6.5 FRANCE
7.6.6 KEY GOVERNING BODIES IN FRANCE
7.6.6.1 National Agency for the Safety of Medicine and Health Products (ANMS)
7.6.6.1.1 Overview
7.6.6.1.2 Responsibilities
7.6.7 ITALY
7.6.8 KEY GOVERNING BODIES IN ITALY
7.6.8.1 Ministry of Health (MOH)
7.6.8.1.1 Overview
7.6.8.1.2 Responsibilities
7.6.8.2 Italian Medicines Agency
7.6.8.2.1 Overview
7.6.8.2.2 Responsibilities
8 REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING
IN ASIA-PACIFIC
8.1 ASIA-PACIFIC
8.2 ASIA-PACIFIC: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
8.2.1 CHINA
8.2.2 KEY GOVERNING BODIES IN CHINA
8.2.2.1 China Food and Drug Administration (CFDA)
8.2.2.1.1 Overview
8.2.2.1.2 Responsibilities
8.2.3 JAPAN
8.2.4 KEY GOVERNING BODIES IN JAPAN
8.2.4.1 Ministry of Health, Labor and Welfare (MHLW)
8.2.4.1.1 Overview
8.2.4.1.2 Responsibilities
8.2.5 INDIA
8.2.6 KEY GOVERNING BODIES IN INDIA
8.2.6.1 Central Drugs Standard Control Organization (CDSCO)
8.2.6.1.1 Overview
8.2.6.1.2 Responsibilities
8.2.7 AUSTRALIA
8.2.8 KEY GOVERNING BODIES IN AUSTRALIA
8.2.8.1 Therapeutic Goods Administration (TGA)
8.2.8.1.1 Overview
8.2.8.1.2 Responsibilities
9 REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN ROW
9.1 ROW
9.2 ROW: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
9.2.1 BRAZIL
9.2.2 KEY GOVERNING BODIES IN BRAZIL
9.2.2.1 National Health Surveillance Agency (ANVISA)
9.2.2.1.1 Overview
9.2.2.1.2 Responsibilities
9.2.3 ARGENTINA
9.2.4 KEY GOVERNING BODIES IN ARGENTINA
9.2.4.1 National Administration of Drugs, Foodstuffs, and Medical Technology (ANMAT)
9.2.4.1.1 Overview
9.2.4.1.2 Responsibilities
9.2.5 SOUTH AFRICA
9.2.6 KEY GOVERNING BODIES IN SOUTH AFRICA
9.2.6.1 Medicines Control Council (MCC)
9.2.6.1.1 Overview
9.2.6.1.2 Responsibilities
10 APPENDIX
10.1 INSIGHTS OF INDUSTRY EXPERTS
10.2 DISCUSSION GUIDE
10.3 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
10.4 AVAILABLE CUSTOMIZATIONS
10.5 RELATED REPORTS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 PERIODIZATION CONSIDERED FOR THE STERILE MEDICAL PACKAGING MARKET
1.4 CURRENCY CONSIDERED FOR THE STERILE MEDICAL PACKAGING MARKET
1.5 UNIT CONSIDERED FOR THE STERILE MEDICAL PACKAGING MARKET
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key Data From Secondary Sources
2.1.2 PRIMARY DATA
2.1.2.1 Key Data From Primary Sources
2.1.2.1.1 Breakdown of primaries by company type, designation & region
2.2 FACTOR ANALYSIS
2.2.1 INTRODUCTION
2.2.2 OVERVIEW OF PARENT INDUSTRY
2.2.3 DEMAND-SIDE ANALYSIS
2.2.3.1 Rising Population
2.2.3.1.1 Increase in the middle-class population, 2009–2030
2.2.3.2 Increasing Urban population
2.2.3.3 Developing Economies: GDP (Purchasing Power Parity)
2.2.4 SUPPLY-SIDE ANALYSIS
2.2.4.1 Fluctuation in Raw Material Prices
2.2.4.2 Increasing Investment in Research & Development to Develop Innovative Technologies
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS & LIMITATIONS
2.5.1 ASSUMPTIONS
2.5.2 LIMITATIONS
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 REGULATORY SCENARIO
3.2.1 REGULATORY FRAMEWORK IN NORTH AMERICA
3.2.2 REGULATORY FRAMEWORK IN ASIA-PACIFIC
3.2.3 REGULATORY FRAMEWORK IN EUROPE
3.2.4 REGULATORY FRAMEWORK IN ROW
3.3 MEDICAL DEVICE APPROVAL PROCESS IN KEY COUNTRIES
3.4 IMPACT ANALYSIS
3.4.1 CASE STUDY: MEDICAL DEVICE RECALL & ITS IMPACT
3.4.2 NEED FOR HARMONIZATION OF GLOBAL STANDARDS & REGULATIONS
4 MARKET OVERVIEW OF STERILE MEDICAL PACKAGING
4.1 INTRODUCTION
4.2 EVOLUTION
4.3 MARKET DYNAMICS
4.3.1 DRIVERS
4.3.1.1 Increased Health Awareness
4.3.1.2 Growing Demand from Healthcare Industry
4.3.1.3 Aging Population
4.3.2 RESTRAINTS
4.3.2.1 Stringent Regulations
4.3.3 OPPORTUNITIES
4.3.3.1 New Product Development and Continuous Innovations in Pharmaceuticals
4.3.3.2 Developing New Sustainable Packaging Options
4.3.4 CHALLENGES
4.3.4.1 Maintaining Medical Packaging Integrity
4.3.4.2 Rise in Healthcare Cost
4.4 STERILE MEDICAL PACKAGE DEVELOPMENT
4.5 FUNCTIONS OF A STERILE MEDICAL PACKAGE
4.5.1 PROTECTION
4.5.2 EASE OF USE
4.5.3 IDENTIFICATION
4.5.4 PROCESSABILITY
4.5.5 SPECIAL APPLICATIONS
5 INTERNATIONAL GOVERNING BODIES
5.1 INTRODUCTION
5.2 AMERICAN SOCIETY FOR TESTING AND MATERIALS (ASTM)
5.2.1 ASTM COMMITTEE D10
5.2.1.1 D10.13
5.2.1.2 D10.19
5.2.1.3 D10.27
5.2.1.4 D10.32
5.2.2 ASTM COMMITTEE F02
5.2.2.1 F02.10
5.2.2.2 F02.15
5.2.2.3 F02.20
5.2.2.4 F02.40
5.2.2.5 F02.50
5.3 INTERNATIONAL ORGANIZATION OF STANDARDIZATION (ISO)
5.3.1 DEVELOPING ISO STANDARDS
5.3.1.1 Preliminary Stage
5.3.1.2 Proposal Stage
5.3.1.3 Preparatory Stage
5.3.1.4 Committee Stage
5.3.1.5 Enquiry Stage
5.3.1.6 Approval Stage
5.3.1.7 Publication Stage
5.3.2 STANDARDS RELATED TO STERILE MEDICAL PACKAGING
5.3.2.1 ISO 16775
5.3.2.2 ISO 11607
5.3.2.2.1 Application
5.3.2.2.2 Limitation
5.3.2.3 ISO 11607-1
5.3.2.4 ISO 11607-2
5.4 U.S. FOOD AND DRUG ADMINISTRATION (FDA)
5.5 INTERNATIONAL MEDICAL DEVICE REGULATORY FORUM (IMDRF)
6 REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN NORTH AMERICA
6.1 NORTH AMERICA
6.2 NORTH AMERICA: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
6.2.1 U.S.
6.2.2 KEY GOVERNING BODIES IN THE U.S.
6.2.2.1 FDA
6.2.2.1.1 Overview
6.2.2.1.2 Responsibilities
6.2.3 CANADA
6.2.4 KEY GOVERNING BODIES IN CANADA
6.2.4.1 Health Canada (HC)
6.2.4.1.1 Overview
6.2.4.1.2 Responsibilities
6.2.5 MEXICO
6.2.6 KEY GOVERNING BODIES IN MEXICO
6.2.6.1 Federal Commission for the Protection Against Sanitary Risk (COFEPRIS)
6.2.6.1.1 Overview
6.2.6.1.2 Responsibilities
7 REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN EUROPE
7.1 EUROPE
7.2 EUROPE: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
7.3 GOVERNING BODIES IN EUROPE
7.3.1 EUROPEAN COMMITTEE FOR STANDARDIZATION (CEN)
7.3.1.1 Overview
7.3.1.2 Standards Developed by CEN
7.3.1.2.1 Harmonization of EN 868-1 and ISO 11607
7.3.1.2.2 EN 868-2: 2009
7.3.1.2.3 EN 868-3:2009
7.3.1.2.4 EN 868-4:2009
7.3.1.2.5 EN 868-5:2009
7.3.1.2.6 EN 868-6:2009
7.3.1.2.7 EN 868-7:2009
7.3.1.2.8 EN 868-8:2009
7.3.1.2.9 EN 868-9:2009
7.3.1.2.10 EN 868-10:2009
7.3.2 STERILE BARRIER ASSOCIATION (SBA)
7.3.2.1 Overview
7.3.2.2 SBA Member Categories
7.3.2.3 Administering Activities
7.4 MEDICAL DEVICE REGULATIONS IN EUROPE
7.4.1 INTRODUCTION
7.4.2 MEDICAL DEVICE DIRECTIVE (93/42/EEC)
7.5 IMPACT OF MEDICAL DEVICE REGULATIONS IN EUROPE
7.5.1 CE MARKING- A GATEWAY TO ACCESS EUROPEAN MARKET
7.5.2 IMPACT OF HARMONIZATION BETWEEN EN AND ISO
7.6 KEY COUNTRIES IN EUROPE
7.6.1 GERMANY
7.6.2 KEY GOVERNING BODIES IN GERMANY
7.6.2.1 Federal Ministry of Health
7.6.2.1.1 Overview
7.6.2.1.2 Administering activities
7.6.2.2 German Institute for Standardization (DIN)
7.6.2.2.1 Overview
7.6.2.2.2 Organizational structure
7.6.2.2.3 Administering activities
7.6.3 U.K.
7.6.4 KEY GOVERNING BODIES IN THE U.K.
7.6.4.1 Medicines and Healthcare products Regulatory Agency (MHRA)
7.6.4.1.1 Overview
7.6.4.1.2 Responsibilities
7.6.4.2 Department of Health (DH)
7.6.4.2.1 Overview
7.6.4.2.2 Responsibilities
7.6.4.3 Association of British Healthcare Industries (ABHI)
7.6.4.3.1 Overview
7.6.4.3.2 Responsibilities
7.6.4.4 The British Standards Institution (BSI)
7.6.4.4.1 Overview
7.6.4.4.2 Responsibilities
7.6.5 FRANCE
7.6.6 KEY GOVERNING BODIES IN FRANCE
7.6.6.1 National Agency for the Safety of Medicine and Health Products (ANMS)
7.6.6.1.1 Overview
7.6.6.1.2 Responsibilities
7.6.7 ITALY
7.6.8 KEY GOVERNING BODIES IN ITALY
7.6.8.1 Ministry of Health (MOH)
7.6.8.1.1 Overview
7.6.8.1.2 Responsibilities
7.6.8.2 Italian Medicines Agency
7.6.8.2.1 Overview
7.6.8.2.2 Responsibilities
8 REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING
IN ASIA-PACIFIC
8.1 ASIA-PACIFIC
8.2 ASIA-PACIFIC: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
8.2.1 CHINA
8.2.2 KEY GOVERNING BODIES IN CHINA
8.2.2.1 China Food and Drug Administration (CFDA)
8.2.2.1.1 Overview
8.2.2.1.2 Responsibilities
8.2.3 JAPAN
8.2.4 KEY GOVERNING BODIES IN JAPAN
8.2.4.1 Ministry of Health, Labor and Welfare (MHLW)
8.2.4.1.1 Overview
8.2.4.1.2 Responsibilities
8.2.5 INDIA
8.2.6 KEY GOVERNING BODIES IN INDIA
8.2.6.1 Central Drugs Standard Control Organization (CDSCO)
8.2.6.1.1 Overview
8.2.6.1.2 Responsibilities
8.2.7 AUSTRALIA
8.2.8 KEY GOVERNING BODIES IN AUSTRALIA
8.2.8.1 Therapeutic Goods Administration (TGA)
8.2.8.1.1 Overview
8.2.8.1.2 Responsibilities
9 REGULATORY FRAMEWORK FOR STERILE MEDICAL PACKAGING IN ROW
9.1 ROW
9.2 ROW: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY
9.2.1 BRAZIL
9.2.2 KEY GOVERNING BODIES IN BRAZIL
9.2.2.1 National Health Surveillance Agency (ANVISA)
9.2.2.1.1 Overview
9.2.2.1.2 Responsibilities
9.2.3 ARGENTINA
9.2.4 KEY GOVERNING BODIES IN ARGENTINA
9.2.4.1 National Administration of Drugs, Foodstuffs, and Medical Technology (ANMAT)
9.2.4.1.1 Overview
9.2.4.1.2 Responsibilities
9.2.5 SOUTH AFRICA
9.2.6 KEY GOVERNING BODIES IN SOUTH AFRICA
9.2.6.1 Medicines Control Council (MCC)
9.2.6.1.1 Overview
9.2.6.1.2 Responsibilities
10 APPENDIX
10.1 INSIGHTS OF INDUSTRY EXPERTS
10.2 DISCUSSION GUIDE
10.3 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
10.4 AVAILABLE CUSTOMIZATIONS
10.5 RELATED REPORTS
LIST OF TABLES
Table 1 ASIA-PACIFIC: URBANIZATION PROSPECTS
Table 2 TECHNICAL SUBCOMMITTEES
Table 3 TECHNICAL SUBCOMMITTEES
Table 4 ANNEX
Table 5 ISO 11607-1
Table 6 ISO 11607-2
Table 7 NORTH AMERICA: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 8 NORTH AMERICA: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (MILLION UNITS)
Table 9 EUROPE: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 10 EUROPE: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
Table 11 EN 868-2:2009
Table 12 IMPLEMENTATION OF EN 868-2:2009 IN EUROPEAN COUNTRIES
Table 13 EN 868-3:2009
Table 14 IMPLEMENTATION OF EN 868-3:2009 IN EUROPEAN COUNTRIES
Table 15 EN 868-4:2009
Table 16 IMPLEMENTATION OF EN 868-4:2009 IN EUROPEAN COUNTRIES
Table 17 EN 868-5:2009
Table 18 IMPLEMENTATION OF EN 868-5:2009 IN EUROPEAN COUNTRIES
Table 19 EN 868-6:2009
Table 20 IMPLEMENTATION OF EN 868-6:2009 IN EUROPEAN COUNTRIES
Table 21 EN 868-7:2009
Table 22 IMPLEMENTATION OF EN 868-7:2009 IN EUROPEAN COUNTRIES
Table 23 EN 868-8:2009
Table 24 IMPLEMENTATION OF EN 868-8:2009 IN EUROPEAN COUNTRIES
Table 25 EN 868-9:2009
Table 26 IMPLEMENTATION OF EN 868-9:2009 IN EUROPEAN COUNTRIES
Table 27 EN 868-10:2009
Table 28 IMPLEMENTATION OF EN 868-10:2009 IN EUROPEAN COUNTRIES
Table 29 STANDARDS PUBLISHED BY NA 063-04-04 AA
Table 30 ASIA-PACIFIC: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 31 ASIA-PACIFIC: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (MILLION UNITS)
Table 32 ROW: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 33 ROW: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (MILLION UNITS)
Table 1 ASIA-PACIFIC: URBANIZATION PROSPECTS
Table 2 TECHNICAL SUBCOMMITTEES
Table 3 TECHNICAL SUBCOMMITTEES
Table 4 ANNEX
Table 5 ISO 11607-1
Table 6 ISO 11607-2
Table 7 NORTH AMERICA: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 8 NORTH AMERICA: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (MILLION UNITS)
Table 9 EUROPE: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 10 EUROPE: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013-2020 (MILLION UNITS)
Table 11 EN 868-2:2009
Table 12 IMPLEMENTATION OF EN 868-2:2009 IN EUROPEAN COUNTRIES
Table 13 EN 868-3:2009
Table 14 IMPLEMENTATION OF EN 868-3:2009 IN EUROPEAN COUNTRIES
Table 15 EN 868-4:2009
Table 16 IMPLEMENTATION OF EN 868-4:2009 IN EUROPEAN COUNTRIES
Table 17 EN 868-5:2009
Table 18 IMPLEMENTATION OF EN 868-5:2009 IN EUROPEAN COUNTRIES
Table 19 EN 868-6:2009
Table 20 IMPLEMENTATION OF EN 868-6:2009 IN EUROPEAN COUNTRIES
Table 21 EN 868-7:2009
Table 22 IMPLEMENTATION OF EN 868-7:2009 IN EUROPEAN COUNTRIES
Table 23 EN 868-8:2009
Table 24 IMPLEMENTATION OF EN 868-8:2009 IN EUROPEAN COUNTRIES
Table 25 EN 868-9:2009
Table 26 IMPLEMENTATION OF EN 868-9:2009 IN EUROPEAN COUNTRIES
Table 27 EN 868-10:2009
Table 28 IMPLEMENTATION OF EN 868-10:2009 IN EUROPEAN COUNTRIES
Table 29 STANDARDS PUBLISHED BY NA 063-04-04 AA
Table 30 ASIA-PACIFIC: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 31 ASIA-PACIFIC: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (MILLION UNITS)
Table 32 ROW: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 33 ROW: STERILE MEDICAL PACKAGING MARKET SIZE, BY COUNTRY, 2013–2020 (MILLION UNITS)
LIST OF FIGURES
Figure 1 GLOBAL POPULATION PROJECTED TO REACH ?9.5 BILLION BY 2050
Figure 2 MIDDLE-CLASS POPULATION, 2009-2030
Figure 3 PROJECTED GDP PER CAPITA, BY COUNTRY
Figure 4 FLUCTUATIONS IN PRICE OF NATURAL GAS FROM 2008 TO 2015
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 NORTH AMERICA DOMINATED THE STERILE MEDICAL PACKAGING MARKET IN 2014
Figure 8 MEDICAL DEVICES APPROVAL PROCESS IN EUROPE
Figure 9 MEDICAL DEVICES APPROVAL PROCESS IN CHINA
Figure 10 MEDICAL DEVICES APPROVAL PROCESS IN AUSTRALIA
Figure 11 PROCESS TO SUPPLY IMPORTED MEDICAL DEVICES IN AUSTRALIA
Figure 12 MEDICAL DEVICES APPROVAL PROCESS IN JAPAN
Figure 13 MEDICAL DEVICES APPROVAL PROCESS IN BRAZIL
Figure 14 REASONS FOR MEDICAL DEVICE PRODUCT RECALLS
Figure 15 EVOLUTION OF STERILE MEDICAL PACKAGING
Figure 16 STERILE MEDICAL PACKAGING MARKET DYNAMICS
Figure 17 REVENUE GENERATED BY PHARMACEUTICALS AND MEDICINES IN THE U.S.
Figure 18 GLOBAL AGING POPULATION, 2010-2015
Figure 19 NUMBER OF RECALLS, 2010-2012
Figure 20 SPENDING ON RETAIL PRESCRIPTION DRUGS
Figure 21 ISO STANDARDS PORTFOLIO, BY SECTOR, 2014
Figure 22 DEVELOPMENT PROCESS FOR ISO STANDARDS
Figure 23 MEDICAL DEVICE CIRCLE
Figure 24 MEDICAL DEVICES APPROVAL PROCESS BY FDA
Figure 25 FDA: ORGANIZATION CHART
Figure 26 HEALTH CANADA: ORGANIZATION CHART
Figure 27 FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISK: ORGANIZATION STRUCTURE
Figure 28 FEDERAL MINISTRY OF HEALTH: ORGANIZATION CHART
Figure 29 MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY: ORGANIZATIONAL STRUCTURE
Figure 30 DEPARTMENT OF HEALTH: ORGANIZATION CHART
Figure 31 ASSOCIATION OF BRITISH HEALTHCARE INDUSTRIES: ORGANIZATION STRUCTURE
Figure 32 THE BRITISH STANDARDS INSTITUTION: ORGANIZATION STRUCTURE
Figure 33 NATIONAL AGENCY FOR THE SAFETY OF MEDICINE AND HEALTH PRODUCTS: ORGANIZATION CHART
Figure 34 MINISTRY OF HEALTH: ORGANIZATION STRUCTURE
Figure 35 ITALIAN MEDICINES AGENCY: ORGANIZATION CHART
Figure 36 MINISTRY OF HEALTH, LABOR AND WELFARE: ORGANIZATION STRUCTURE
Figure 37 CENTRAL DRUGS STANDARD CONTROL ORGANIZATION: ORGANIZATION STRUCTURE
Figure 38 THERAPEUTIC GOODS ADMINISTRATION: ORGANIZATION STRUCTURE
Figure 39 MEDICINES CONTROL COUNCIL: ORGANIZATION STRUCTURE
Figure 1 GLOBAL POPULATION PROJECTED TO REACH ?9.5 BILLION BY 2050
Figure 2 MIDDLE-CLASS POPULATION, 2009-2030
Figure 3 PROJECTED GDP PER CAPITA, BY COUNTRY
Figure 4 FLUCTUATIONS IN PRICE OF NATURAL GAS FROM 2008 TO 2015
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 NORTH AMERICA DOMINATED THE STERILE MEDICAL PACKAGING MARKET IN 2014
Figure 8 MEDICAL DEVICES APPROVAL PROCESS IN EUROPE
Figure 9 MEDICAL DEVICES APPROVAL PROCESS IN CHINA
Figure 10 MEDICAL DEVICES APPROVAL PROCESS IN AUSTRALIA
Figure 11 PROCESS TO SUPPLY IMPORTED MEDICAL DEVICES IN AUSTRALIA
Figure 12 MEDICAL DEVICES APPROVAL PROCESS IN JAPAN
Figure 13 MEDICAL DEVICES APPROVAL PROCESS IN BRAZIL
Figure 14 REASONS FOR MEDICAL DEVICE PRODUCT RECALLS
Figure 15 EVOLUTION OF STERILE MEDICAL PACKAGING
Figure 16 STERILE MEDICAL PACKAGING MARKET DYNAMICS
Figure 17 REVENUE GENERATED BY PHARMACEUTICALS AND MEDICINES IN THE U.S.
Figure 18 GLOBAL AGING POPULATION, 2010-2015
Figure 19 NUMBER OF RECALLS, 2010-2012
Figure 20 SPENDING ON RETAIL PRESCRIPTION DRUGS
Figure 21 ISO STANDARDS PORTFOLIO, BY SECTOR, 2014
Figure 22 DEVELOPMENT PROCESS FOR ISO STANDARDS
Figure 23 MEDICAL DEVICE CIRCLE
Figure 24 MEDICAL DEVICES APPROVAL PROCESS BY FDA
Figure 25 FDA: ORGANIZATION CHART
Figure 26 HEALTH CANADA: ORGANIZATION CHART
Figure 27 FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISK: ORGANIZATION STRUCTURE
Figure 28 FEDERAL MINISTRY OF HEALTH: ORGANIZATION CHART
Figure 29 MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY: ORGANIZATIONAL STRUCTURE
Figure 30 DEPARTMENT OF HEALTH: ORGANIZATION CHART
Figure 31 ASSOCIATION OF BRITISH HEALTHCARE INDUSTRIES: ORGANIZATION STRUCTURE
Figure 32 THE BRITISH STANDARDS INSTITUTION: ORGANIZATION STRUCTURE
Figure 33 NATIONAL AGENCY FOR THE SAFETY OF MEDICINE AND HEALTH PRODUCTS: ORGANIZATION CHART
Figure 34 MINISTRY OF HEALTH: ORGANIZATION STRUCTURE
Figure 35 ITALIAN MEDICINES AGENCY: ORGANIZATION CHART
Figure 36 MINISTRY OF HEALTH, LABOR AND WELFARE: ORGANIZATION STRUCTURE
Figure 37 CENTRAL DRUGS STANDARD CONTROL ORGANIZATION: ORGANIZATION STRUCTURE
Figure 38 THERAPEUTIC GOODS ADMINISTRATION: ORGANIZATION STRUCTURE
Figure 39 MEDICINES CONTROL COUNCIL: ORGANIZATION STRUCTURE
